Director/PDMR Shareholding
SAVILLS PLC (THE "COMPANY")
DIRECTOR'S SHARE PURCHASE
The Company announces that it has received notification that Stacey Cartwright, an Independent Non-Executive Director, has today purchased 2,860 Savills plc ordinary shares of 2.5p each ("Ordinary Shares") at £8.63 per share. As a result, Ms. Cartwright has a total beneficial interest in 2,860 Ordinary Shares, representing 0.002% of the Company's issued share capital.
The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities/ person closely associated
| ||
(a) | Name | Stacey Cartwright
| |
2. | Reason for the notification
| ||
(a) | Position/ status | Independent Non-Executive Director
| |
(b) | Initial notification/ Amendment
| Initial notification | |
3. | Details of the issuer
| ||
(a) | Name | Savills plc
| |
(b) | LEI | 213800WXICGMBWHTA933
| |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
(a) | Description of the Financial Instrument
| Savills plc Ordinary Shares of 2.5p each | |
(b) | Identification code of the Financial Instrument
| GB00B135BJ46 | |
(c) | Nature of the transaction
| Purchase of Ordinary Shares
| |
(d) | Price(s) and volume(s)
| Price(s) | Volume(s)
|
£8.63 per share
| 2,860 | ||
(e) | Aggregated information
- Aggregated volume - Price
| N/A
| |
(f) | Date of the transaction
| 10 September 2019 | |
(g) | Place of the transaction
| London Stock Exchange (XLON) |
Name of contact and telephone number for queries:
Chris Lee
Group Legal Director & Company Secretary
020 3107 5444
10 September 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.